Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

(2020) Yelena Y Janjigian et al.   LANCET ONCOLOGY

Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?

(2020) Yukiya Narita et al.   LANCET ONCOLOGY

Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis

(2019) Hoibin Jeong et al.   CANCER RESEARCH

The function and potential drug targets of tumour-associated Tregs for cancer immunotherapy

(2019) Shanshan Yan et al.   Science China-Life Sciences

Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway

(2019) Yipin Lv et al.   Journal for ImmunoTherapy of Cancer

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

3D models in the new era of immune oncology: focus on T cells, CAF and ECM

(2019) Francesca Di Modugno et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC).

(2019) Vaibhav G. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE ‐023 study

(2019) Maria‐Victoria Mateos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?

(2019) Yoshihiro Ohue et al.   CANCER SCIENCE

Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy

(2019) Debarati Banik et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors.

(2019) Chan Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

(2019) Thomas Yau et al.   JOURNAL OF CLINICAL ONCOLOGY

Rational design of anti-GITR-based combination immunotherapy

(2019) Roberta Zappasodi et al.   NATURE MEDICINE

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

(2019) Abdullah Al Emran et al.   TRENDS IN IMMUNOLOGY

Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition

(2019) Maike Trommer et al.   Frontiers in Pharmacology

Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors

(2019) Yoshikatsu Koga et al.   Cells

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

(2019) Li-Chuan Chan et al.   JOURNAL OF CLINICAL INVESTIGATION

Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression

(2019) Atsunori Kamiya et al.   NATURE NEUROSCIENCE

An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses

(2019) Ismail M. Meraz et al.   Cancer Immunology Research

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

(2019) Venkatesh Sivanandam et al.   Molecular Therapy-Oncolytics

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

(2019) Alexandra S. Zimmer et al.   Journal for ImmunoTherapy of Cancer

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

(2019) Jhanelle E. Gray et al.   CLINICAL CANCER RESEARCH

Complex interactions between the microbiome and cancer immune therapy

(2019) Drew J. Schwartz et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Prospects for combining immune checkpoint blockade with PARP inhibition

(2019) Anping Li et al.   Journal of Hematology & Oncology

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

(2019) Meena Bansal et al.   BLOOD

Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy

(2019) Diana C. Márquez-Garbán et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

The Intriguing History of Cancer Immunotherapy

(2019) Paula Dobosz et al.   Frontiers in Immunology

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

(2018) HS Rugo et al.   CANCER RESEARCH

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer

(2018) Suk Hyung Lee et al.   CELL

Metformin for non-small cell lung cancer patients: Opportunities and pitfalls

(2018) Antonin Levy et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis

(2018) Linjie Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

(2018) Georgios Vlachogiannis et al.   SCIENCE

Role of Immunotherapy in Head and Neck Cancer

(2018) Diane C. Ling et al.   SEMINARS IN RADIATION ONCOLOGY

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

(2018) Wantong Song et al.   Nature Communications

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

(2018) Na Luo et al.   Nature Communications

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

(2018) Rebekka Weber et al.   Frontiers in Immunology

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression

(2018) Viktor Fleming et al.   Frontiers in Immunology

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

(2018) Karin M. Knudson et al.   OncoImmunology

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

(2018) Rikke B. Holmgaard et al.   Journal for ImmunoTherapy of Cancer

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.

(2018) Alan Anthoney et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

(2018) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

(2018) Yiyi Yan et al.   Frontiers in Immunology

Development of PARP and Immune-Checkpoint Inhibitor Combinations

(2018) Ross A Stewart et al.   CANCER RESEARCH

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis

(2018) Brian W. Labadie et al.   CLINICAL CANCER RESEARCH

TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer

(2018) Daniel R Principe et al.   MOLECULAR CANCER THERAPEUTICS

MDSC; the Most Important Cell You Have Never Heard Of

(2018) R.J. Tesi   TRENDS IN PHARMACOLOGICAL SCIENCES

Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases

(2017) Benjamin Frey et al.   IMMUNOLOGICAL REVIEWS

A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells

(2017) Irina Kareva   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

(2017) Christian Manegold et al.   Journal of Thoracic Oncology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

(2017) Matthias Pinter et al.   Science Translational Medicine

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine

(2017) Chantal Pauli et al.   Cancer Discovery

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models

(2017) Shujin Cui   MEDICAL SCIENCE MONITOR

Myeloid-Derived Suppressor Cells

(2017) Dmitry I. Gabrilovich   Cancer Immunology Research

Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice

(2017) Kathleen M. Kokolus et al.   OncoImmunology

Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery

(2017) Dana Haddad   Frontiers in Oncology

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

(2016) J. Fucikova et al.   BLOOD

Immune suppressive mechanisms in the tumor microenvironment

(2016) David H Munn et al.   CURRENT OPINION IN IMMUNOLOGY

The emerging role of immune checkpoint inhibition in malignant lymphoma

(2016) Ida Hude et al.   HAEMATOLOGICA

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

(2016) Guido Bocci et al.   Nature Reviews Clinical Oncology

The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism

(2016) Peter Spanogiannopoulos et al.   NATURE REVIEWS MICROBIOLOGY

Impact of Immune-Modulatory Drugs on Regulatory T Cell

(2016) Akiko Furukawa et al.   TRANSPLANTATION

Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells

(2016) Nikolaos Svoronos et al.   Cancer Discovery

Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma

(2016) Ludovic Jean Wrobel et al.   Oncotarget

The emerging role of immune checkpoint inhibition in malignant lymphoma

(2016) Ida Hude et al.   HAEMATOLOGICA

Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells

(2016) Martin König et al.   Frontiers in Immunology

Immunotherapy of melanoma: Present options and future promises

(2015) Anand Rotte et al.   CANCER AND METASTASIS REVIEWS

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

(2015) Irina Kareva et al.   CANCER LETTERS

Immune modulation in advanced radiotherapies: Targeting out-of-field effects

(2015) Gerard G. Hanna et al.   CANCER LETTERS

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2015) J. A. Califano et al.   CLINICAL CANCER RESEARCH

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+T Cells

(2015) Xiaoyun Lu et al.   JOURNAL OF IMMUNOLOGY

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

(2015) Shingo Eikawa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer

(2015) Zibing Wang et al.   Oncotarget

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Pharmacological DNA demethylation: Implications for cancer immunotherapy

(2015) David Roulois et al.   OncoImmunology

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation

(2014) Huaqin Yuan et al.   BIOMEDICINE & PHARMACOTHERAPY

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

(2014) B. Farsaci et al.   Cancer Immunology Research

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Immune-suppressive properties of the tumor microenvironment

(2013) Jürgen C. Becker et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Angiotensin II Drives the Production of Tumor-Promoting Macrophages

(2013) Virna Cortez-Retamozo et al.   IMMUNITY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

(2013) Nathan J. Robison et al.   PEDIATRIC BLOOD & CANCER

An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer

(2013) E. B. Golden et al.   Cancer Immunology Research

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

(2012) Giacomo Allegrini et al.   ANGIOGENESIS

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy

(2012) Mariana S. Nars et al.   INTERNATIONAL JOURNAL OF CANCER

Structure, function and diversity of the healthy human microbiome

(2012)   NATURE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells

(2012) Chang W. Song et al.   Scientific Reports

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

(2011) O A Khan et al.   BRITISH JOURNAL OF CANCER

Immunotherapeutic modulation of the suppressive liver and tumor microenvironments

(2011) Tim Chan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy

(2010) Michael Bader   Annual Review of Pharmacology and Toxicology

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer

(2010) M. Bodmer et al.   DIABETES CARE

Angiotensin-converting enzyme is required for normal myelopoiesis

(2010) Chentao Lin et al.   FASEB JOURNAL

Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

(2010) I. Ben Sahra et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Classification of Chemotherapeutic Agents Based on Their Differential In vitro Effects on Dendritic Cells

(2009) H. Tanaka et al.   CANCER RESEARCH

Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients

(2009) D. Generali et al.   CLINICAL CANCER RESEARCH

Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib

(2009) J. Ma et al.   CLINICAL CANCER RESEARCH

HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer

(2009) A López-Soto et al.   ONCOGENE

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer

(2008) Yoshihiko Kitajima et al.   CANCER SCIENCE